Form 4: Apogee Therapeutics Chief Medical Officer Executes Stock Transactions
SEC Form 4 Filing
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, acquired and disposed of company stock and stock options on December 11, 2024, according to a recent SEC filing.
Summary
- Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, engaged in multiple transactions involving the company's stock on December 11, 2024.
- He acquired 1,815 shares of common stock at a price of $22.86 per share through the exercise of stock options.
- He also sold 4,085 shares at $48.62 per share and 455 shares at $50 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2024.
- Following these transactions, Dambkowski directly owns 258,073 shares of common stock and holds options for 173,530 shares.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. It is a neutral event.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives.
Comparison to Industry Standards
- The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
- The reported transactions are typical for executives who hold stock options and are part of their compensation packages.
- Similar filings are regularly made by executives at comparable biotech companies such as Regeneron, Vertex, and BioMarin.
Stakeholder Impact
- The transactions may have a minor impact on the stock price, but are unlikely to significantly affect shareholders.
- The transactions are part of the executive's compensation and do not directly impact employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 08/21/2024 | Date the Rule 10b5-1 trading plan was adopted. |
| 12/11/2024 | Date of the stock and option transactions. |
| 12/13/2024 | Date the SEC Form 4 was signed. |
| 12/18/2027 | End of the vesting period for the stock options. |
| 12/18/2033 | Expiration date of the stock options. |
Keywords
Apogee Therapeutics, Carl Dambkowski, stock transactions, SEC Form 4, Rule 10b5-1, insider trading, stock options, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.